🚀 VC round data is live in beta, check it out!
Ultragenyx Valuation Multiples
Discover revenue and EBITDA valuation multiples for Ultragenyx and similar public comparables like Pfizer India, Ascentage Pharma Group, Bavarian Nordic, ADMA Biologics and more.
Ultragenyx Overview
About Ultragenyx
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.
Founded
2010
HQ
Employees
1.4K
Website
Sectors
Financials (LTM)
EV
$2B
Ultragenyx Financials
Ultragenyx reported last 12-month revenue of $699M and negative EBITDA of ($476M).
In the same LTM period, Ultragenyx generated $591M in gross profit, ($476M) in EBITDA losses, and had net loss of ($537M).
Revenue (LTM)
Ultragenyx P&L
In the most recent fiscal year, Ultragenyx reported revenue of $673M and EBITDA of ($474M).
Ultragenyx expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $699M | XXX | $673M | XXX | XXX | XXX |
| Gross Profit | $591M | XXX | $564M | XXX | XXX | XXX |
| Gross Margin | 84% | XXX | 84% | XXX | XXX | XXX |
| EBITDA | ($476M) | XXX | ($474M) | XXX | XXX | XXX |
| EBITDA Margin | (68%) | XXX | (70%) | XXX | XXX | XXX |
| EBIT Margin | (72%) | XXX | (79%) | XXX | XXX | XXX |
| Net Profit | ($537M) | XXX | ($575M) | XXX | XXX | XXX |
| Net Margin | (77%) | XXX | (85%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Ultragenyx Stock Performance
Ultragenyx has current market cap of $2B, and enterprise value of $2B.
Market Cap Evolution
Ultragenyx's stock price is $23.91.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | 3.3% | XXX | XXX | XXX | $-5.85 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialUltragenyx Valuation Multiples
Ultragenyx trades at 2.4x EV/Revenue multiple, and (3.6x) EV/EBITDA.
EV / Revenue (LTM)
Ultragenyx Financial Valuation Multiples
As of April 11, 2026, Ultragenyx has market cap of $2B and EV of $2B.
Equity research analysts estimate Ultragenyx's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Ultragenyx has a P/E ratio of (4.4x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/Revenue | 2.4x | XXX | 2.5x | XXX | XXX | XXX |
| EV/EBITDA | (3.6x) | XXX | (3.6x) | XXX | XXX | XXX |
| EV/EBIT | (3.4x) | XXX | (3.2x) | XXX | XXX | XXX |
| EV/Gross Profit | 2.9x | XXX | 3.0x | XXX | XXX | XXX |
| P/E | (4.4x) | XXX | (4.1x) | XXX | XXX | XXX |
| EV/FCF | 4.6x | XXX | 4.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Ultragenyx Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Ultragenyx Margins & Growth Rates
Ultragenyx's revenue in the last 12 month grew by 20%.
Ultragenyx's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.8M for the same period.
Ultragenyx's rule of 40 is (32%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Ultragenyx's rule of X is (11%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Ultragenyx Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 20% | XXX | 14% | XXX | XXX | XXX |
| EBITDA Margin | (68%) | XXX | (70%) | XXX | XXX | XXX |
| EBITDA Growth | (39%) | XXX | (25%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (32%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (11%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.8M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 46% | XXX | 49% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 105% | XXX | 111% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 163% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Ultragenyx Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Pfizer India | XXX | XXX | XXX | XXX | XXX | XXX |
| Ascentage Pharma Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Bavarian Nordic | XXX | XXX | XXX | XXX | XXX | XXX |
| ADMA Biologics | XXX | XXX | XXX | XXX | XXX | XXX |
| Sarepta Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Ultragenyx M&A Activity
Ultragenyx acquired XXX companies to date.
Last acquisition by Ultragenyx was on XXXXXXXX, XXXXX. Ultragenyx acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Ultragenyx
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialUltragenyx Investment Activity
Ultragenyx invested in XXX companies to date.
Ultragenyx made its latest investment on XXXXXXXX, XXXXX. Ultragenyx invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Ultragenyx
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Ultragenyx
| When was Ultragenyx founded? | Ultragenyx was founded in 2010. |
| Where is Ultragenyx headquartered? | Ultragenyx is headquartered in United States. |
| How many employees does Ultragenyx have? | As of today, Ultragenyx has over 1K employees. |
| Who is the CEO of Ultragenyx? | Ultragenyx's CEO is Emil D. Kakkis. |
| Is Ultragenyx publicly listed? | Yes, Ultragenyx is a public company listed on Nasdaq. |
| What is the stock symbol of Ultragenyx? | Ultragenyx trades under RARE ticker. |
| When did Ultragenyx go public? | Ultragenyx went public in 2014. |
| Who are competitors of Ultragenyx? | Ultragenyx main competitors are Pfizer India, Ascentage Pharma Group, Bavarian Nordic, ADMA Biologics. |
| What is the current market cap of Ultragenyx? | Ultragenyx's current market cap is $2B. |
| What is the current revenue of Ultragenyx? | Ultragenyx's last 12 months revenue is $699M. |
| What is the current revenue growth of Ultragenyx? | Ultragenyx revenue growth (NTM/LTM) is 20%. |
| What is the current EV/Revenue multiple of Ultragenyx? | Current revenue multiple of Ultragenyx is 2.4x. |
| Is Ultragenyx profitable? | No, Ultragenyx is not profitable. |
| What is the current EBITDA of Ultragenyx? | Ultragenyx has negative EBITDA and is not profitable. |
| What is Ultragenyx's EBITDA margin? | Ultragenyx's last 12 months EBITDA margin is (68%). |
| What is the current EV/EBITDA multiple of Ultragenyx? | Current EBITDA multiple of Ultragenyx is (3.6x). |
| What is the current FCF of Ultragenyx? | Ultragenyx's last 12 months FCF is $375M. |
| What is Ultragenyx's FCF margin? | Ultragenyx's last 12 months FCF margin is 54%. |
| What is the current EV/FCF multiple of Ultragenyx? | Current FCF multiple of Ultragenyx is 4.6x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.